MX363510B - Vacuna con coronavirus respiratorio canino para proteccion contra infecciones de b. bronchiseptica. - Google Patents

Vacuna con coronavirus respiratorio canino para proteccion contra infecciones de b. bronchiseptica.

Info

Publication number
MX363510B
MX363510B MX2014014652A MX2014014652A MX363510B MX 363510 B MX363510 B MX 363510B MX 2014014652 A MX2014014652 A MX 2014014652A MX 2014014652 A MX2014014652 A MX 2014014652A MX 363510 B MX363510 B MX 363510B
Authority
MX
Mexico
Prior art keywords
vaccination
protection against
respiratory coronavirus
canine respiratory
bronchiseptica
Prior art date
Application number
MX2014014652A
Other languages
English (en)
Other versions
MX2014014652A (es
Inventor
Shelly Lynn Shields
Omar Yousif Abdelmagid
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of MX2014014652A publication Critical patent/MX2014014652A/es
Publication of MX363510B publication Critical patent/MX363510B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente memoria se proporcionan composiciones, combinaciones y procedimientos que comprenden el coronavirus respiratorio canino (CRC0V), que son eficaces en el tratamiento o la prevención de infecciones respiratorias asociadas a patógenos secundarios, tales como Bordetella bronchiseptica, en animales.
MX2014014652A 2012-05-31 2013-05-24 Vacuna con coronavirus respiratorio canino para proteccion contra infecciones de b. bronchiseptica. MX363510B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653558P 2012-05-31 2012-05-31
PCT/US2013/042590 WO2013181086A1 (en) 2012-05-31 2013-05-24 Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections

Publications (2)

Publication Number Publication Date
MX2014014652A MX2014014652A (es) 2015-02-24
MX363510B true MX363510B (es) 2019-03-26

Family

ID=48626613

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014652A MX363510B (es) 2012-05-31 2013-05-24 Vacuna con coronavirus respiratorio canino para proteccion contra infecciones de b. bronchiseptica.

Country Status (13)

Country Link
US (1) US10632189B2 (es)
EP (1) EP2854847B1 (es)
JP (1) JP6313752B2 (es)
CN (1) CN104411330B (es)
AU (1) AU2013267716B2 (es)
BR (1) BR112014029725B1 (es)
CA (1) CA2874966C (es)
EA (1) EA032284B1 (es)
ES (1) ES2748205T3 (es)
HK (1) HK1206265A1 (es)
MX (1) MX363510B (es)
NZ (1) NZ701930A (es)
WO (1) WO2013181086A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7474023B2 (ja) 2018-03-14 2024-04-24 新光電子株式会社 押込み試験装置
JP2022540197A (ja) * 2019-07-12 2022-09-14 リサーチ ディベロップメント ファウンデーション エーリキアワクチンおよび免疫原性組成物
RU2733831C1 (ru) * 2020-07-08 2020-10-07 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Искусственный ген, кодирующий бицистронную структуру, образованную последовательностями рецептор-связующего домена гликопротеина S коронавируса SARS-CoV-2, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_SC2, обеспечивающая экспрессию искусственного гена и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_SC2, используемого для создания вакцины против коронавируса SARS-CoV-2
RU2768749C1 (ru) * 2021-06-07 2022-03-24 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Средство специфической профилактики covid-19 для плотоядных животных

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571618A1 (fr) 1984-10-12 1986-04-18 Virbac Ctre Rech Biolog Nouveau vaccin contre la tracheobronchite infectieuse canine et son procede de preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU2001249300B2 (en) * 2000-04-03 2006-02-16 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
GB0217434D0 (en) * 2002-07-27 2002-09-04 Royal Vetinary College Biological material
DE10237102A1 (de) * 2002-08-13 2004-02-26 Bayerische Motoren Werke Ag Integralbremsanlage für Motorräder
PL378001A1 (pl) 2003-01-29 2006-02-20 Pfizer Products Inc. Szczepionki przeciw Bordetella bronchiseptica dla psów
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
HUE062920T2 (hu) * 2006-12-27 2023-12-28 Zoetis Services Llc Eljárások vakcina beadására
EP2544717B1 (en) 2010-03-10 2018-08-15 Intervet International B.V. Method for protecting against disease caused by secondary pathogens
CN103596588B (zh) * 2011-02-04 2016-02-03 佐蒂斯有限责任公司 用于犬呼吸道疾病综合征的组合物
BR112013019675B8 (pt) * 2011-02-04 2022-11-22 Zoetis Services Llc Composições imunogênicas de bordetella bronchiseptica
WO2012103821A2 (zh) * 2012-03-09 2012-08-09 华为技术有限公司 天线系统、基站和通信系统

Also Published As

Publication number Publication date
BR112014029725B1 (pt) 2023-09-26
BR112014029725A2 (pt) 2017-06-27
CN104411330B (zh) 2017-02-22
EP2854847A1 (en) 2015-04-08
ES2748205T3 (es) 2020-03-13
US20150157706A1 (en) 2015-06-11
AU2013267716B2 (en) 2018-03-08
EA032284B1 (ru) 2019-05-31
NZ701930A (en) 2016-10-28
BR112014029725A8 (pt) 2018-04-03
EA201401202A1 (ru) 2015-08-31
AU2013267716A1 (en) 2014-11-27
MX2014014652A (es) 2015-02-24
CA2874966C (en) 2020-06-09
HK1206265A1 (en) 2016-01-08
CA2874966A1 (en) 2013-12-05
JP2015518047A (ja) 2015-06-25
EP2854847B1 (en) 2019-08-07
CN104411330A (zh) 2015-03-11
JP6313752B2 (ja) 2018-04-18
US10632189B2 (en) 2020-04-28
WO2013181086A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
MX2014010455A (es) Metodos y composiciones para tratar enfermedad de huntington.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
ZA201504458B (en) Treatment compositions comprising microcapsules, primary or secondary amines, and formaldehyde scavengers
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
WO2014052836A3 (en) Methods and compositions for treating infection
MX352962B (es) Compuestos para tratar atrofia muscular espinal.
MY173518A (en) Antimicrobial compounds and methods of making and using the same
MX2015012576A (es) Composiciones a base de nanoparticulas.
ECSP14011792A (es) Inhibidores de iap
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
GB2518813A (en) OMV vaccine against Burkholderia infections
CY1124093T1 (el) Ανοσογονικες συνθεσεις bordetella bronchiseptica
MX2022015141A (es) Composiciones y metodos de uso de un compuesto de control de inapetencia.
NZ701930A (en) Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
HK1220358A1 (zh) 減毒活甲病毒製劑的組合物和方法
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.
IL236476A0 (en) Preparations and methods for the treatment or prevention of infection with the pneumovirus and diseases related to it
HK1215682A1 (zh) 用於治療或預防齲齒的組合物、用途和方法
IN2013MU03216A (es)
MX350718B (es) Vacuna de rinitis equina.
MX2016004961A (es) Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
BR112013019850A8 (pt) Composições de vacina e seu uso no tratamento ou prevenção de doenças respiratórias infecciosas caninas